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enrolled in the WHI study were overweight, 80% were
between 60 and 79 years old, half had smoked and some had
hypertension and increased concentrations of cholesterol.
These cardiovascular risk factors suggest that many in the
study could have had established atherosclerosis.
Recent studies suggest HRT may inhibit the process of
atherosclerosis in healthy arteries soon after menopause 3, and
observational studies in younger women starting HRT suggest
a potential cardiovascular benefit.4 However, HRT may have
a deleterious effect by destabilising plaques in the
atherosclerotic arteries of older women. Secondary prevention
studies such as HERS 5 confirm an early increase in adverse
cardiovascular events when HRT is first prescribed after a
cardiac event.
To improve the power of the study for cardiac events the
WHI enrolled many older women, with cardiovascular risk
factors, up to the age of 79 years. To what extent the effect
of combined HRT seen in the WHI population applies to
women commencing HRT at perimenopause remains
debatable. The cardiovascular results of WHI are going to
remain controversial until healthier and younger
postmenopausal women are studied in a long-term trial. When
counselling older women one could show the results of
WHI (Fig. 1). A summary of the statistically significant results
of major outcomes (Fig. 2) may help simplify counselling in
younger women around the menopause.
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SYNOPSIS
The Women’s Health Initiative Study was stopped because
of safety concerns about hormone replacement therapy
with oestrogen and progestogen. There was an increase in
breast cancer, however this was not greater than the
increase reported in observational studies. Although there
was an increase in vascular events, many of the women in
the study had pre-existing risk factors for cardiovascular
disease. No long-term trials of combined hormone
replacement therapy are continuing, so the balance between
benefit and harm will remain uncertain. Hormone
replacement therapy can still be prescribed for
menopausal symptoms and for osteoporosis prevention,
but the need for continued use should be reviewed
annually.
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Introduction
The premature cessation of one arm of the ongoing US Women’s
Health Initiative study (WHI) undoubtedly caused more media
alarm than scientific alarm.1 This study is very important, as it
was one of only two studies of long-term hormone replacement
therapy (HRT). Although the combined oestrogen and
progestogen arm was stopped the dietary and oestrogen-only
arms continue. The combined HRT arm was stopped because
the predetermined stopping point (a small but statistically
significant increase in detected breast cancer) was reached. In
addition, there was an increase in stroke and thromboembolism,
and a trend to an increase in heart disease (Fig. 1).
Although breast cancer increased (by 8 cases per 10 000
women years) there was no overall difference in cancer rates
or mortality between the placebo and combined HRT groups.
This was because HRT was associated with a reduction in
bowel and uterine cancers. The results observed in the WHI
study were of similar magnitude as those seen in the systematic
reanalysis of observational studies2 of women taking combined
oestrogen and progestogen (Table 1). The early cessation of
this arm of the study at 5.2 years prevents the assessment of
later benefits and risks.
Cardiovascular disease
The reported results of WHI to date are little different from the
published results of randomised trials looking at the
secondary prevention of heart disease. Most women
Event rates in the Women's Health Initiative Study
Fig. 1
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Unresolved issues
A long-term randomised trial can study only a few therapeutic
regimens. Only conjugated equine oestrogens and
medroxyprogesterone acetate were being tested in the
long-term HRT trials, WHI and WISDOM (Women’s
International Study of long Duration Oestrogen after
Menopause). No other HRT regimens are being tested. It is
therefore impossible to know if HRT by non-oral routes,
Summary of significant risks and benefits after
5 years of HRT*
Table 1
Comparison of outcomes from the Women’s Health Initiative and observational studies *
Outcome after 5 years of Relative risk (+ CI) † Hazard ratio (+ adjusted CI)
combined hormone in systematic reviews of in WHI study at 5.2 years ‡
replacement therapy observational studies
Cancer
Invasive breast2 1.35 (1.21–1.49)§ 1.26 (0.83–1.92)
1.53‡
Endometrial7 0.80 (0.6–1.2) 0.83 (0.29–2.32)
Colorectal8 0.72 (0.53–0.96) 0.63 (0.32–1.24)
Total – 1.03 (0.86–1.22)
Fractures
Hip9 0.60 (0.4–0.91) 0.66 (0.33–1.33)
Vertebral10 0.67 (0.45–0.98) 0.66 (0.32–1.34)
Total – 0.76 (0.63–0.92)
Cardiovascular disease
Stroke11 1.45 (1.10–1.92) 1.41 (0.86–2.31)
Thromboembolism12 2.14 (1.64–2.81) 2.11 (1.26–3.55)
Coronary heart disease 1.29 (0.85–1.97)
Observational studies4 0.66 (0.53–0.84)
HERS# overall5 0.99 (0.8–1.22)
HERS# mortality 1.24 (0.87–1.75)
Total mortality – 0.98 (0.70–1.37)
* Observational studies and randomised controlled trials cannot be directly compared but it is reassuring to see the magnitude of effect is
similar in this case.
† Confidence interval
‡ Combined oestrogen and progestogen regimens
§ All regimens of hormone replacement therapy
# The Heart and Estrogen/Progestin Replacement Study (HERS) was a randomised placebo-controlled trial.
other oestrogens, other progestogens or other drugs such as
tibolone have different effects. It would be wise to counsel that
the outcomes for other combined HRT products may be
similar to those reported by the WHI.
To date, oestrogen-only HRT does not have the same risk
profile as combined oestrogen and progestogen and the
oestrogen-only arm of the WHI study continues. Most
importantly the WHI study does not give the overall
harm:benefit ratio for long-term HRT as many outcomes were
not measured. These include quality of life, menopausal
symptom control, cognitive function, dementia, urogenital
health, arthritis, other cancers and the effects of HRT on other
body parts, e.g. eyes, teeth, skin. All these outcomes and a
better understanding of the effects of HRT on the cardiovascular
system are still greatly needed. WISDOM (the UK, Australian
and New Zealand 15-year trial of HRT) was looking at these
outcomes, but the study has been discontinued.6 It is unlikely
that we shall ever have good evidence to assess the risks,
benefits and costs of long-term HRT.
It is important to emphasise that short-term trials of HRT
show clear evidence of benefit for menopausal symptoms,
especially vasomotor symptoms. These studies also show
adverse effects which include start-up bleeding, breast
tenderness and the uncommon but early risk of
thromboembolism. The risk of breast cancer does not
significantly increase until after five years of first use of
combined HRT. The most pessimistic increase in breast cancer
in all studies to date is one extra-detected breast cancer per 100
women after 10 years of use, but without an increase in breast
cancer mortality. In women who have had a premature
menopause and who require earlier HRT their risk at age 55 is
approximately that of women commencing HRT at age 50.
Long-term use in these women up to age 55 is appropriate.
Fig. 2






















* Although increased stroke and heart attacks were seen in the US
WHI population, this population had many pre-existing risk factors
for these problems. The effect of HRT on the blood vessels of younger,
healthier women around menopause requires further study.
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What to do now
It is not appropriate to prescribe HRT without an indication.
The following points act as a guide to good practice.
• The main indication for HRT is for the control of
menopausal symptoms and where quality of life is improved
on HRT.
• Always counsel about the mixed risks and benefits of HRT
and document this counselling. Supplementary written
and video counselling is available from the Australasian
Menopause Society web site (www.menopause.org.au).
• Oral HRT is still the route of choice. Women with a uterus
require combined HRT, giving the progestogen cyclically
over perimenopause and continuously after menopause.
Women with a uterus should not receive oestrogen alone.
• In women who only have urogenital symptoms local
vaginal oestrogens can be used.
• In women at risk of osteoporotic fractures, discuss and
tailor the individual evidence-based therapies such as
HRT, selective oestrogen receptor modulators or
bisphosphonates, together with lifestyle advice.
• HRT is not advocated for the treatment or prevention of
cardiovascular disease.
• Women on HRT should be reviewed yearly to determine
optimal therapy and time for cessation of treatment.
• After 4–5 years of therapy it is appropriate to offer a trial
off HRT. The dose can be reduced over 1–2 months before
cessation.
• In women who have a return of disabling symptoms, HRT
can be re-introduced for further treatment periods at the
lowest effective dose and at any time of their lives.
• Women who are aware of the currently known mixed
benefits and risks of long-term therapy and who have
found that they have a better quality of life on HRT can be
prescribed long-term HRT.
E-mail: alastair.maclennan@adelaide.edu.au
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Self-test questions
The following statements are either true or false
(answers on page 23)
3. The risk of breast cancer reported in the Women’s
Health Initiative study, of combined hormone
replacement therapy, was significantly greater than
the risk reported in previous observational studies.
4. Hormone replacement therapy should no longer be
prescribed for the relief of menopausal symptoms.
Australian Prescriber wallchart
Copies of the wallchart ‘Medical management of severe
anaphylactoid and anaphylactic reactions’ which was
published with Vol. 24 No. 5 of 2001, are available for
surgeries, clinics, hospitals and consulting rooms while
stocks last.
To order copies contact the Australian Prescriber Mailing
Service (see inside back cover for details).
